Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti–COVID-19 drug design

Wioletta Rut(Wrocław University of Science and Technology), Zongyang Lv(The University of Texas at San Antonio Health Science Center), Mikołaj Żmudziński(Wrocław University of Science and Technology), Stephanie Patchett(New York University), Digant Nayak(The University of Texas at San Antonio Health Science Center), Scott J. Snipas(Sanford Burnham Prebys Medical Discovery Institute), Farid El Oualid(Corbion (Netherlands)), Tony T. Huang(New York University), Miklós Békés, Marcin Drąg(Wrocław University of Science and Technology), Shaun K. Olsen(The University of Texas at San Antonio Health Science Center)
Science Advances
October 16, 2020
Cited by 482Open Access
Full Text

Abstract

Viral papain-like cysteine protease (PLpro, NSP3) is essential for SARS-CoV-2 replication and represents a promising target for the development of antiviral drugs. Here, we used a combinatorial substrate library and performed comprehensive activity profiling of SARS-CoV-2 PLpro. On the scaffold of the best hits from positional scanning, we designed optimal fluorogenic substrates and irreversible inhibitors with a high degree of selectivity for SARS PLpro. We determined crystal structures of two of these inhibitors in complex with SARS-CoV-2 PLpro that reveals their inhibitory mechanisms and provides a molecular basis for the observed substrate specificity profiles. Last, we demonstrate that SARS-CoV-2 PLpro harbors deISGylating activity similar to SARSCoV-1 PLpro but its ability to hydrolyze K48-linked Ub chains is diminished, which our sequence and structure analysis provides a basis for. Together, this work has revealed the molecular rules governing PLpro substrate specificity and provides a framework for development of inhibitors with potential therapeutic value or drug repurposing.


Related Papers